Reis IM - Search Results

1

Phase II clinical trials in oncology: strengths and limitations of two-stage designs.

Schlesselman JJ, Reis IM. Schlesselman JJ, et al. Among authors: reis im. Cancer Invest. 2006 Jun-Jul;24(4):404-12. doi: 10.1080/07357900600705516. Cancer Invest. 2006. PMID: 16777694 Review.

2

Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.

Singal R, Ferdinand L, Reis IM, Schlesselman JJ. Singal R, et al. Among authors: reis im. Oncol Rep. 2004 Sep;12(3):631-7. Oncol Rep. 2004. PMID: 15289848

3

Polymorphisms in the methylenetetrahydrofolate reductase gene and prostate cancer risk.

Singal R, Ferdinand L, Das PM, Reis IM, Schlesselman JJ. Singal R, et al. Among authors: reis im. Int J Oncol. 2004 Nov;25(5):1465-71. Int J Oncol. 2004. PMID: 15492840

4

Polymorphisms in the DNA methyltransferase 3b gene and prostate cancer risk.

Singal R, Das PM, Manoharan M, Reis IM, Schlesselman JJ. Singal R, et al. Among authors: reis im. Oncol Rep. 2005 Aug;14(2):569-73. Oncol Rep. 2005. PMID: 16012746

5

Methylation mediated silencing of TMS1/ASC gene in prostate cancer.

Das PM, Ramachandran K, Vanwert J, Ferdinand L, Gopisetty G, Reis IM, Singal R. Das PM, et al. Among authors: reis im. Mol Cancer. 2006 Jul 18;5:28. doi: 10.1186/1476-4598-5-28. Mol Cancer. 2006. PMID: 16848908 Free PMC article.

6

Serum GADD45a methylation is a useful biomarker to distinguish benign vs malignant prostate disease.

Reis IM, Ramachandran K, Speer C, Gordian E, Singal R. Reis IM, et al. Br J Cancer. 2015 Jul 28;113(3):460-8. doi: 10.1038/bjc.2015.240. Epub 2015 Jul 14. Br J Cancer. 2015. PMID: 26171936 Free PMC article.

7

Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target.

Ramachandran K, Gopisetty G, Gordian E, Navarro L, Hader C, Reis IM, Schulz WA, Singal R. Ramachandran K, et al. Among authors: reis im. Cancer Res. 2009 Feb 15;69(4):1527-35. doi: 10.1158/0008-5472.CAN-08-3609. Epub 2009 Feb 3. Cancer Res. 2009. PMID: 19190346

8

Serum free circulating DNA is a useful biomarker to distinguish benign versus malignant prostate disease.

Gordian E, Ramachandran K, Reis IM, Manoharan M, Soloway MS, Singal R. Gordian E, et al. Among authors: reis im. Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1984-91. doi: 10.1158/1055-9965.EPI-10-0287. Epub 2010 Jul 20. Cancer Epidemiol Biomarkers Prev. 2010. PMID: 20647404

9

Free circulating DNA as a biomarker of prostate cancer: comparison of quantitation methods.

Ramachandran K, Speer CG, Fiddy S, Reis IM, Singal R. Ramachandran K, et al. Among authors: reis im. Anticancer Res. 2013 Oct;33(10):4521-9. Anticancer Res. 2013. PMID: 24123025

10

Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy.

Singal R, Ramachandran K, Gordian E, Quintero C, Zhao W, Reis IM. Singal R, et al. Among authors: reis im. Clin Genitourin Cancer. 2015 Feb;13(1):22-31. doi: 10.1016/j.clgc.2014.07.008. Epub 2014 Aug 1. Clin Genitourin Cancer. 2015. PMID: 25178642 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters